Related Experiment Video
Updated: May 24, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
Glycosylated fibronectin in preeclampsia: a systematic review and meta-analysis
Lingyun Liao1,2, Min Liu1,2, Yangxue Yin1,2
1Department of Obstetrics and Gynecology, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, (Sichuan University) of Ministry of Education, Chengdu, China.
Insights
Maternal serum glycosylated fibronectin (GlyFn) levels are significantly elevated in preeclampsia (PE) patients. This meta-analysis confirms GlyFn’s high diagnostic accuracy, supporting its use as a biomarker for PE screening and diagnosis.
Area of Science:
- Reproductive Medicine
- Biomarkers
- Diagnostic Accuracy
Background:
- Preeclampsia (PE) is a serious pregnancy complication impacting maternal and infant health.
- Elevated maternal serum glycosylated fibronectin (GlyFn) has been observed in PE patients.
- GlyFn shows potential as a novel biomarker for PE screening and diagnosis.
Purpose of the Study:
- To evaluate maternal serum GlyFn levels in preeclampsia.
- To assess the diagnostic accuracy of GlyFn for preeclampsia.
Main Methods:
- Systematic literature search of PubMed, EMBASE, Web of Science, and Cochrane Library.
- Meta-analysis of 11 studies comparing maternal serum GlyFn levels in PE vs. controls.
- Assessed diagnostic accuracy using pooled sensitivity, specificity, and area under the curve (AUC).
Main Results:
- Maternal serum GlyFn levels were significantly higher in the PE group (SMD = 1.08).
- The pooled sensitivity for GlyFn in diagnosing PE was 0.81.
- The pooled specificity was 0.80, with an AUC of 0.90.
Conclusions:
- Maternal serum GlyFn levels are significantly elevated in preeclampsia.
- GlyFn demonstrates high diagnostic accuracy for preeclampsia.
- GlyFn is a promising biomarker for PE screening and diagnosis.
Background:
Preeclampsia (PE) is a complex multisystem disease, and its timely diagnosis and treatment impact the health of patients and perinatal infants. Studies have reported elevated levels of maternal serum glycosylated fibronectin (GlyFn) in patients with PE compared with pregnant women without PE (controls), suggesting its potential as a novel biomarker for screening and diagnosing PE. Therefore, this study aims to evaluate maternal serum GlyFn levels and their diagnostic accuracy in PE.
Methods:
A systematic literature search was conducted using PubMed, EMBASE, Web of Science, and the Cochrane Library up to January 15, 2024. The Newcastle-Ottawa Quality Assessment Scale and the Quality Assessment of Diagnostic Accuracy Studies-2 tool were used to evaluate study quality. Heterogeneity was assessed using I2 statistics. In the meta-analysis comparing maternal serum GlyFn levels between PE and controls, standardized mean differences (SMDs) and 95% confidence intervals (CIs) were calculated. Publication bias was detected, and sensitivity and subgroup analyses were conducted to verify the robustness of the results and identify potential sources of heterogeneity. For the meta-analysis of diagnostic, the accuracy of maternal serum GlyFn levels between PE and controls, sensitivity and specificity were pooled and the summary receiver operating characteristic curve and area under the curve were used as measures of overall accuracy. This review was registered in the International Prospective Register of Systematic Reviews (registration number: CRD42024512172).
Results:
A total of 11 studies were included, and the meta-analysis revealed that maternal serum GlyFn levels were significantly higher in the PE group than in the control group (SMD = 1.08, 95% CI = 0.72-1.43, P < 0.001). Heterogeneity may arise from differences in the detection method and research type. Overall, the combined sensitivity and specificity of maternal serum GlyFn levels in diagnosing PE were 0.81 (95% CI = 0.77-0.85, P < 0.001) and 0.80 (95% CI = 0.77-0.82, P < 0.001), respectively, with an area under the curve of 0.90.
Conclusions:
This meta-analysis confirmed that maternal serum GlyFn levels are significantly higher in patients with PE and exhibit high diagnostic accuracy for PE diagnosis, suggesting its potential as a biomarker for screening and diagnosing PE.
Related Concept Videos
Proteoglycans
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Hormonal Regulation
Fibronectins Connect Cells with ECM
Both proteoglycans and collagen are attached to fibronectin proteins, which, in turn, are attached to integrin proteins. These integrin proteins interact with transmembrane...
Oligosaccharide Assembly
Multiple sugar molecules that may or may...

